{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"96"}]}],"title":"Complete Response, 6 months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"110"}]}],"title":"Complete Response, 2 years"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"50"}]}],"title":"No Evidence of Leukemia, 6 months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"42"}]}],"title":"No Evidence of Leukemia, 2 years"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"29"}]}],"title":"Minor Response, 6 months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"28"}]}],"title":"Minor Response, 2 years"},{"categories":[{"measurements":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"130"}]}],"title":"No Response, 6 months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"125"}]}],"title":"No Response, 2 years"},{"categories":[{"measurements":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"146"}]}],"title":"MaHR, 6 months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"152"}]}],"title":"MaHR, 2 years"},{"categories":[{"measurements":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"175"}]}],"title":"Overall Response, 6 months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"180"}]}],"title":"Overall Response, 2 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"306"},{"groupId":"OG001","value":"305"}],"units":"Participants"}],"description":"Type of hematologic response: CHR defined as: WBC ≤ ULN; ANC ≥ 1,000/mm\\^3; - platelets ≥ 100,000/mm\\^3; - no blasts or promyelocytes in PB; BM blasts ≤ 5%; \\< 5% myelocytes plus metamyelocytes in PB; basophils in PB \\< 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by the same criteria as CHR except that platelets and ANC had to satisfy at least one of the following (note that both lower limits had to be satisfied): platelets ≥ 20,000/mm\\^3 and \\<100,000/mm\\^3; ANC \\> 500/mm\\^3 and \\<1,000/mm\\^3. Minor Hematologic Response (MiHR): \\<15% blasts in BM and in PB; \\< 30% blasts + promyelocytes in BM and PB; \\< 20% basophils in PB; No extra-medullary disease other than spleen and liver. Major hematologic response (MaHR ) was CHR or NEL. Overall hematologic response was CHR or NEL or MiHR.","groups":[{"description":"Dasatinib was administered orally at a dose of 140 mg once a day (QD) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant.","id":"OG000","title":"Dasatinib 140 mg QD"},{"description":"Dasatinib was administered orally at a dose of 70 mg twice a day (BID) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant..","id":"OG001","title":"Dasatinib 70 mg BID"}],"paramType":"NUMBER","populationDescription":"Participants were analyzed based on the treatment they were randomized to receive.","reportingStatus":"POSTED","timeFrame":"Randomization up to 6 months, 2 years","title":"Number of Participants With Best Confirmed Hematologic Response, Major Hematologic Response (MaHR) and Overall Hematologic Response - Randomized Population","type":"SECONDARY","unitOfMeasure":"participants"}